Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Biotechnologijos

Mr. Joe  Lewcock Ph.D.

Chief Scientific Officer

Mr. Tyler M. Nielsen

Senior Vice President of Corporate Finance

Dr. Dana  Andersen

Chief Technical and Manufacturing Officer

Dr. Ryan J. Watts Ph.D.

Co-Founder, President, Chief Executive Officer & Director

Dr. Carole  Ho M.D.

Chief Medical Officer & Head of Development

Dr. Laura  Hansen

Vice President of Investor Relations

Dr. Marc  Tessier-Lavigne Ph.D.

Co-Founder & Independent Director

Mr. Chris  Walsh

General Counsel

Mr. Mark  Rowen

Vice President of Corporate Development

Dr. Alexander O. Schuth M.D.

Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary

Pavadinimas	Rinkos kapitalizacija
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Denali Therapeutics Inc.

Denali Therapeutics Inc. Konkurentų sąrašas

Pagrindiniai konkurentai